Diabetes Research Group

Welcome to the University of Ulster Diabetes Research Group homepage. On this website you will find a comprehensive overview of the background, strategy, membership, focus research areas and technology transfer activities of our Research Group. The Diabetes Research Group has established substantial collaborative networks and placed considerable effort into the training and professional development of undergraduate, postgraduate (MSc, MRes, MPhil/PhD, MD) and postdoctoral researchers. We welcome you to browse through our site and feel free to contact us for further information on research and collaborative opportunities.


Introduction

The Diabetes Research Group was formed in 1989, following the appointment of Professor Peter Flatt to a Chair of Biological and Biomedical Sciences. A significant expansion of the Group with the academic appointments of Professor Finbarr O’Harte (1995), Professor Neville McClenaghan (1998), Dr Aine McKillop (2002), Dr Victor Gault (2004), Dr Yasser Abdel-Wahab (2007) and Dr Alyson Hill (2007) has strengthened the research profile and capitalised on the Group’s policy of research endeavor and selectivity.



Since 1989 the Group has built an extensive range of external networks being the founder of the European Association for the Study of Diabetes (EASD) Islet Study Group and playing a pivotal role in the establishment of the EU-funded Islet Research European and Latin-American Networks. The Group has also played a key role in diabetes research both nationally and internationally through senior positions in the British Diabetic Association / Diabetes UK, the EASD and establishing rich collaborations with numerous Centres of Excellence worldwide. The Group’s activities are expanding and the formation of a province-wide HPSS funded RRG in Diabetes and Endocrinology has strengthened local clinical collaborations.


Activities of the Group have been strategically directed into four thrust areas, aiming to increase knowledge at the forefront of diabetes research and subsequently develop new approaches for diabetes therapy. Group activities have contributed to the award of the highest grade of 5* in the 1996, 2001 and 2008 HEFCE Research Assessment Exercise encompassing a spectrum of state of the art technologies coupled with strong clinical research collaborations.